UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (70) 70
humans (68) 68
life sciences & biomedicine (68) 68
oncology (50) 50
male (45) 45
female (44) 44
aged (40) 40
middle aged (37) 37
lung neoplasms - drug therapy (36) 36
carcinoma, non-small-cell lung - drug therapy (34) 34
chemotherapy (30) 30
lung cancer, non-small cell (27) 27
cancer (26) 26
carcinoma, non-small-cell lung - pathology (26) 26
lung cancer (26) 26
adult (25) 25
lung neoplasms - pathology (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
respiratory system (22) 22
life sciences (20) 20
aged, 80 and over (18) 18
neoplasm staging (17) 17
carcinoma, non-small-cell lung - mortality (16) 16
treatment outcome (16) 16
lung neoplasms - mortality (15) 15
cisplatin - administration & dosage (14) 14
lung neoplasms (14) 14
metastasis (14) 14
non-small-cell lung cancer (14) 14
antineoplastic agents - therapeutic use (13) 13
care and treatment (13) 13
erlotinib (13) 13
non-small cell lung cancer (13) 13
pulmonary/respiratory (13) 13
analysis (12) 12
carcinoma, non-small-cell lung - economics (12) 12
disease-free survival (12) 12
lung neoplasms - economics (12) 12
lung neoplasms - genetics (12) 12
prognosis (12) 12
prospective studies (12) 12
research (12) 12
santé publique et épidémiologie (12) 12
carcinoma, non-small-cell lung - genetics (11) 11
carcinoma, non-small-cell lung - therapy (11) 11
hematology, oncology and palliative medicine (11) 11
lung neoplasms - therapy (11) 11
mutation (11) 11
survival analysis (11) 11
carcinoma, non-small-cell lung (10) 10
deoxycytidine - analogs & derivatives (10) 10
erlotinib hydrochloride (10) 10
france (10) 10
pulmonary and respiratory medicine (10) 10
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (9) 9
cancer therapies (9) 9
cost-benefit analysis (9) 9
deoxycytidine - administration & dosage (9) 9
mesh: humans (9) 9
oncology, experimental (9) 9
pemetrexed (9) 9
cost analysis (8) 8
guanine - analogs & derivatives (8) 8
kaplan-meier estimate (8) 8
mesh: lung neoplasms (8) 8
quinazolines - therapeutic use (8) 8
antineoplastic agents (7) 7
antineoplastic agents - administration & dosage (7) 7
antineoplastic agents - economics (7) 7
antineoplastic combined chemotherapy protocols (7) 7
development and progression (7) 7
economic aspects (7) 7
follow-up studies (7) 7
medicine & public health (7) 7
mesh: carcinoma, non-small-cell lung (7) 7
mesh: middle aged (7) 7
protein kinase inhibitors - therapeutic use (7) 7
receptor, epidermal growth factor - genetics (7) 7
studies (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
cisplatin (6) 6
cost of illness (6) 6
france - epidemiology (6) 6
general & internal medicine (6) 6
health care sciences & services (6) 6
immunotherapy (6) 6
medicine (6) 6
medicine, general & internal (6) 6
mesh: female (6) 6
mesh: male (6) 6
platinum (6) 6
quality of life (6) 6
quinazolines - administration & dosage (6) 6
quinazolines - economics (6) 6
surgery (6) 6
survival rate (6) 6
time factors (6) 6
bevacizumab (5) 5
carcinoma, squamous cell - pathology (5) 5
clinical trials (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1% or more of tumor cells were randomly assigned to receive nivolumab plus... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
Journal Article
Journal Article
PharmacoEconomics, ISSN 1170-7690, 2009, Volume 27, Issue 2, pp. 113 - 125
... of T reatments for Non-Small Cell Lung Cancer Christos Chouaid, 1,2,3 Kukovi Atsou, 1 Gilles Hejblum 1,4 and Alain Vergnenegre 5 1 INSERM, U707, Paris, France 2 Pierre... 
Quality of Life Research | Health Economics | Health Administration | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | Economics | Social Sciences | Life Sciences & Biomedicine | Health Care Sciences & Services | Pharmacology & Pharmacy | Business & Economics | Health Policy & Services | Science & Technology | Erlotinib Hydrochloride | Carcinoma, Non-Small-Cell Lung - radiotherapy | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - surgery | Guanine - analogs & derivatives | Humans | Guanine - economics | Lung Neoplasms - radiotherapy | Pemetrexed | Combined Modality Therapy - economics | Glutamates - economics | Carcinoma, Non-Small-Cell Lung - economics | Taxoids - therapeutic use | Taxoids - economics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Antineoplastic Combined Chemotherapy Protocols - economics | Lung Neoplasms - surgery | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - economics | Guanine - therapeutic use | Chemotherapy | Care and treatment | Economic aspects | Diagnosis | Radiotherapy | Lung cancer, Non-small cell | Health aspects | Cancer | Studies | Health care expenditures | Health economics | Lung cancer | Medical treatment | Cost analysis | Health technology assessment | Life Sciences | Taxoids | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Santé publique et épidémiologie | Combined Modality Therapy | Quinazolines | Glutamates | Lung Neoplasms | Guanine
Journal Article
PloS one, ISSN 1932-6203, 07/2019, Volume 14, Issue 7, pp. e0219060 - e0219060
Journal Article
by Rosell, Rafael and Carcereny, Enric and Gervais, Radj and Vergnenegre, Alain and Massuti, Bartomeu and Felip, Enriqueta and Palmero, Ramon and Garcia-Gomez, Ramon and Pallares, Cinta and Sanchez, Jose Miguel and Porta, Rut and Cobo, Manuel and Garrido, Pilar and Longo, Flavia and Moran, Teresa and Insa, Amelia and De Marinis, Filippo and Corre, Romain and Bover, Isabel and Illiano, Alfonso and Dansin, Eric and de Castro, Javier and Milella, Michele and Reguart, Noemi and Altavilla, Giuseppe and Jimenez, Ulpiano and Provencio, Mariano and Moreno, Miguel Angel and Terrasa, Josefa and Muñoz-Langa, Jose and Valdivia, Javier and Isla, Dolores and Domine, Manuel and Molinier, Olivier and Mazieres, Julien and Baize, Nathalie and Garcia-Campelo, Rosario and Robinet, Gilles and Rodriguez-Abreu, Delvys and Lopez-Vivanco, Guillermo and Gebbia, Vittorio and Ferrera-Delgado, Lioba and Bombaron, Pierre and Bernabe, Reyes and Bearz, Alessandra and Artal, Angel and Cortesi, Enrico and Rolfo, Christian and Sanchez-Ronco, Maria and Drozdowskyj, Ana and Queralt, Cristina and de Aguirre, Itziar and Ramirez, Jose Luis and Sanchez, Jose Javier and Molina, Miguel Angel and Taron, Miquel and Paz-Ares, Luis and on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
The lancet oncology, ISSN 1470-2045, 03/2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 05/2016, Volume 34, Issue 13, pp. 1476 - 1483
Journal Article
PharmacoEconomics, ISSN 1170-7690, 2006, Volume 24, Issue 7, pp. 651 - 659
Journal Article
Journal Article